Three musketeers of PDA-based MRI contrasting and therapy
Source abstract
Abstract
Polydopamine (PDA) stands as a versatile material explored in cancer nanomedicine for its unique properties, offering opportunities for multifunctional drug delivery platforms. This study explores the potential of utilizing a one-pot synthesis to concurrently integrate Fe, Gd and Mn ions into porous PDA-based theranostic drug delivery platforms called Ferritis, Gadolinis and Manganis, respectively. Our investigation spans the morphology, magnetic properties, photothermal characteristics and cytotoxicity profiles of those potent nanoformulations. The obtained structures showcase a spherical morphology, robust magnetic response and promising photothermal behaviour. All of the presented nanoparticles (NPs) display pronounced paramagnetism, revealing contrasting potential for MRI imaging. Relaxivity values, a key determinant of contrast efficacy, demonstrated competitive or superior performance compared to established, used contrasting agents. These nanoformulations also exhibited robust photothermal properties under near infra-red irradiation, showcasing their possible application for photothermal therapy of cancer. Our findings provide insights into the potential of metal-doped PDA NPs for cancer theranostics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Gold and Silver Nanoparticles Synthesis and Applications · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NanoBioMedical Centre, Adam Mickiewicz University in Poznań, Poznań, Poland
Faculty of Chemistry, Adam Mickiewicz University in Poznań, Poznań, Poland
Centre for Advanced Technologies, Adam Mickiewicz University in Poznań, Poznań, Poland
Funding
National Science Centre, Poland · National Centre for Research and Development
References (66)
Show source-provided references
1. 10.1016/j.nanoso.2019.10039710.1016/j.nanoso.2019.100397 ↗
2. 10.1016/j.ijpharm.2020.11931410.1016/j.ijpharm.2020.119314 ↗
3. 10.1021/acsami.0c1925910.1021/acsami.0c19259 ↗
4. 10.1039/C6TB02249A10.1039/C6TB02249A ↗
5. 10.1186/s12951-022-01698-x10.1186/s12951-022-01698-x ↗
6. 10.1002/adfm.20230420810.1002/adfm.202304208 ↗
7. 10.1016/j.jconrel.2016.05.06210.1016/j.jconrel.2016.05.062 ↗
8. Pérez-Hernández M. Mechanisms of cell death induced by optical hyperthermia. In: R. M. Fratila and J. M. De La Fuente (editors). Nanomaterials for magnetic and optical hyperthermia applications. Elsevier; 2019. p. 201–228.10.1016/B978-0-12-813928-8.00008-9 ↗
9. 10.1002/adfm.20160338110.1002/adfm.201603381 ↗
10. 10.1007/s40005-019-00431-510.1007/s40005-019-00431-5 ↗
11. 10.1016/j.mtbio.2022.10041610.1016/j.mtbio.2022.100416 ↗
12. 10.26434/chemrxiv-2023-nl43g10.26434/chemrxiv-2023-nl43g ↗
13. 10.1021/acsnano.3c0089110.1021/acsnano.3c00891 ↗
14. 10.3390/pharmaceutics1308114710.3390/pharmaceutics13081147 ↗
15. 10.1016/j.biomaterials.2016.10.03010.1016/j.biomaterials.2016.10.030 ↗
16. 10.1021/acsnano.1c0370010.1021/acsnano.1c03700 ↗
17. 10.1021/nn901877h10.1021/nn901877h ↗
18. 10.1021/acsanm.7b0025510.1021/acsanm.7b00255 ↗
19. 10.1021/acsnano.9b0598510.1021/acsnano.9b05985 ↗
20. 10.1021/acsami.6b1025510.1021/acsami.6b10255 ↗
21. 10.1021/nn403617j10.1021/nn403617j ↗
22. 10.1158/0008-5472.CAN-10-455710.1158/0008-5472.CAN-10-4557 ↗
23. 10.1002/smll.20100084710.1002/smll.201000847 ↗
24. 10.1016/j.jphotobiol.2020.11211010.1016/j.jphotobiol.2020.112110 ↗
25. 10.3390/jnt203000910.3390/jnt2030009 ↗
26. 10.1016/j.jconrel.2013.07.02010.1016/j.jconrel.2013.07.020 ↗
27. 10.1200/GO.21.0036610.1200/GO.21.00366 ↗
28. 10.1016/j.carbpol.2020.11650910.1016/j.carbpol.2020.116509 ↗
29. 10.1136/jitc-2022-00470810.1136/jitc-2022-004708 ↗
30. 10.1016/j.nic.2008.06.00410.1016/j.nic.2008.06.004 ↗
31. 10.1021/bm400813810.1021/bm4008138 ↗
32. 10.1002/wnan.185810.1002/wnan.1858 ↗
33. 10.1039/D1RA05544E10.1039/D1RA05544E ↗
34. 10.1002/smll.20190704210.1002/smll.201907042 ↗
35. Kaufman AA Hansen RO Kleinberg RLK. Chapter 6: paramagnetism diamagnetism and ferromagnetism. In: A.A. Kaufman R.O. Hansen R.L.K. Kleinberg (editors) Methods in geochemistry and geophysics; Elsevier 2008. p. 207–254.10.1016/S0076-6895(08)00006-1 ↗
36. Belorizky E Fries PH. Characterising contrast agents for magnetic resonance imaging. In: P. Bertrand (editor) Electron paramagnetic resonance spectroscopy. Cham: Springer International Publishing; 2020. p. 313–349.10.1007/978-3-030-39668-8_11 ↗
37. 10.1016/j.ijbiomac.2023.12582610.1016/j.ijbiomac.2023.125826 ↗
38. 10.1002/ejoc.20190044510.1002/ejoc.201900445 ↗
39. 10.1021/acs.langmuir.1c0078310.1021/acs.langmuir.1c00783 ↗
40. 10.1021/acs.langmuir.0c0004610.1021/acs.langmuir.0c00046 ↗
41. 10.1021/acs.chemmater.8b0433310.1021/acs.chemmater.8b04333 ↗
42. 10.1016/j.jphotobiol.2023.11281310.1016/j.jphotobiol.2023.112813 ↗
43. 10.1007/s11426-018-9392-610.1007/s11426-018-9392-6 ↗
44. 10.1021/acs.chemmater.7b0226210.1021/acs.chemmater.7b02262 ↗
45. 10.1021/acsnano.6b0550210.1021/acsnano.6b05502 ↗
46. 10.1039/D1NR00957E10.1039/D1NR00957E ↗
47. 10.1021/acs.langmuir.6b0329410.1021/acs.langmuir.6b03294 ↗
48. 10.1186/s40169-017-0175-010.1186/s40169-017-0175-0 ↗
49. 10.1039/C7NR01857F10.1039/C7NR01857F ↗
50. 10.3390/pharmaceutics1504128110.3390/pharmaceutics15041281 ↗
51. 10.3389/fphar.2023.108161210.3389/fphar.2023.1081612 ↗
52. 10.2147/IJN.S21863210.2147/IJN.S218632 ↗
53. 10.1016/j.colsurfb.2021.11159610.1016/j.colsurfb.2021.111596 ↗
54. 10.1111/cpr.1313010.1111/cpr.13130 ↗
55. 10.1016/j.actbio.2019.01.00210.1016/j.actbio.2019.01.002 ↗
56. 10.1016/j.biomaterials.2020.12020810.1016/j.biomaterials.2020.120208 ↗
57. 10.2147/IJN.S13141810.2147/IJN.S131418 ↗
58. 10.1021/acsnano.3c1228110.1021/acsnano.3c12281 ↗
59. 10.1021/acs.nanolett.1c0337710.1021/acs.nanolett.1c03377 ↗
60. 10.3390/pharmaceutics1110050710.3390/pharmaceutics11100507 ↗
61. 10.1016/j.jcis.2021.07.00410.1016/j.jcis.2021.07.004 ↗
62. 10.1155/2019/184563710.1155/2019/1845637 ↗
63. 10.1097/01.rli.0000184756.66360.d310.1097/01.rli.0000184756.66360.d3 ↗
64. 10.1039/C8RA04530E10.1039/C8RA04530E ↗
65. 10.1039/c6sc01320a10.1039/c6sc01320a ↗
66. 10.1002/smll.20170183010.1002/smll.201701830 ↗